Insulin affordability in a pressing issue in the United States and more and more pushback is happening from patients and organizations to drive the cost down.
As part of the ongoing efforts to improve access to patients, NovoNordisk has just announced today that they are expanding on their existing programs. Senior Director of Corporate Communications, Ken Inchausti stated in communication with Diabetes Daily that this effort was largely influenced by communication with our team and others at the 79th American Diabetes Association (ADA) Scientific Sessions earlier this year.
Here are the details of the program expansion as provided by the company in their press release:
• $99 Cash Card Program provides 3000 – 3600 Units of any combination of Novo Nordisk analog insulins in vials or pens from Novo Nordisk Inc.
• NovoLog® and NovoLog® Mix follow-on brands (authorized generics) will be available in vials and pens at a 50 percent list price reduction from the newly established Novo Nordisk Pharma Inc.
• New offerings launch in January 2020 and are designed to support those with and without insurance; visit NovoCare.com to learn about existing programs available now
NovoNordisk reinforced that insulin affordability is an ongoing, serious, and complex problem, that must continue to be addressed in a multifaceted way in order to continuously drive positive change:
While we will continue to do what we can to help address affordability challenges in the short-term, changes within the system are required to make sustainable and meaningful affordability a reality. What a patient pays for medicine is influenced by insurance benefit design and pricing. While Novo Nordisk has acknowledged the role of list price, more needs to be done to improve how insurance benefits cover vital medicines, especially through high deductible health plans. Those plans push list prices to patients to fulfill a deductible, which sometimes means paying thousands of dollars.
While reform efforts across the board are needed, informing patients about existing and upcoming discount programs offered by insulin companies is also an important step in helping to mitigate the current crisis for many.
Doug Langa, Executive Vice President, North America Operations and President of Novo Nordisk Inc. stated,
We also want to do more to make people aware of all the programs and options across Novo Nordisk companies that may benefit them and are continuously working to ensure they are easier to access and navigate. We know that people have different challenges depending on their situation and encourage them to contact us to learn how we may be able to help.
Please stay tuned as we continue to bring you policy change updates and new information on ways to save money on insulin costs in the near future. Please share this article and your thoughts in the comments below.
Post Views: 89